It has been suggested that altering the blood flow in tumours might significantly alter the effectiveness of chemotherapy, radiotherapy and thermotherapy and also of targeted therapy with such vectors as monoclonal antibodies (Zanelli & Fowler, 1974; Bomber et al., 1986; Smyth et al., 1987; Chan et al., 1984) . Bomber et al. (1986) showed that the beta-adrenoreceptor blocker propranolol increased tumour perfusion rates in a transplanted mouse sarcoma by two to three fold. This was thought to be due to the drug acting on the heart, reducing cardiac output and blood pressure, which in turn resulted in a compensatory sympathetic vasoconstriction in an attempt to maintain blood pressure. Tumour blood vessels lack smooth muscle (Chan et al., 1984) , and do not respond to the compensatory vasoconstriction. The net consequence was a change in the relative perfusion rates, with an increase in tumour blood flow, although these authors did not report whether there was a change in blood flow rates in other organs. Smyth et al. (1987) used the beta blockers propranolol and pindolol in an attempt to increase localisation of a monoclonal antibody in a transplanted mouse thymoma. Although there was an increase in localisation, there was also up to 50% reduction in blood levels of the antibody. Thus, although there was a good increase in tumour to blood ratios, this was due in large part to the reduced blood survival of the antibody. The reason for this reduction in blood survival was unclear, and there was in fact a reduced level of antibody in all tissues examined (except the tumour), although the whole body retention of the antibody was not reported.
The present study was carried out in nude mice with human tumour xenografts to examine the influence of propranolol and pindolol on tumour blood flow rates, and on the extent of tumour localisation and whole body catabolism of an anti-tumour monoclonal antibody (791T/36) and an isotype matched IgG2b.
Nude mice (Harlan Olac, Oxon, UK) were used throughout. They were housed in isolator cabinets (ACE Isolator Systems Ltd, Powys, UK) with sterile bedding, food and water. Human tumour lines used were the colon carcinomas Colo-205 and HCT8 and the osteosarcoma 791T. All were routinely passaged by aseptic subcutaneous implantation into the flank of the mice of pieces of tissue about 3 mm3. The tumours used in the present studies were 22-27 days old.
Relative blood flow rates, as a proportion of the cardiac output, in tumour and other organs were determined by the method of Sapirstein (1958) , by the intravenous injection of 5 tCi of 86Rb (rubidium chloride, Amersham International, Bucks., UK) with dissection after 2 min (see Sapirstein (1958) and Zanelli and Fowler (1974) To determine their effects on blood flow, propranolol and pindolol (Sigma Chemical Co Ltd, Dorset, UK) were injected intravenously 15 min before the 86Rb at 10 mg kg-', these doses and time of injection relative to the 86Rb being based on those used by Bomber et al. (1986) and Smyth et al. (1987) . Propranolol (as hydrochloride) was dissolved in saline BP, and pindolol in 0.1% w/v tartaric acid in saline BP.
Although both propranolol and pindolol could alter blood flow in organs, with some increase in tumour blood flow, the effects were small and not consistently to the level of statistical significance. In the first test (Table I) , propranolol statistically significantly increased the fractional distribution of 86Rb into 791T tumours from 0.75% of cardiac output g-1 to 1.20%, but also significantly increased spleen, kidney and lung blood flow rates. Although pindolol gave an increase in tumour blood flow rate (to 0.92% g-') this was not statistically significant, but there was no effect on blood flow in any organ. In a repeat test (test 2) in mice with the same tumour, propranolol did increase tumour blood flow, but not to the level of statistical significance. Pindolol had an even weaker effect but it did reduce renal blood flow. In mice with HCT8 xenografts, both propranolol and pindolol statistically increased tumour blood flow from a mean of 0.32% g-' to 0.89% and 0.69% respectively, and propranolol, but not pindolol, significantly increased spleen, liver, kidney and lung blood flow (test 4, Table I ). (There was also a significant increase in the small amount of 86Rb surviving in the blood in propranolol treated mice). In mice with colon carcinoma Colo-205, propranolol had no effect on tumour blood flow (test 5, Table I ). Thus, overall, propranolol increased tumour blood flow in 3/4 tests, but to a statistically significant level in only two Pindolol had some effect in 3/3 tests, but statistically significantly in only one. Only propranolol had widespread effects on 86Rb levels in other tissues, there being an effect in blood in 2/4 tests, spleen in 2/4, kidney in 2/4, liver in 1/4 and lung in 3/4.
To determine the effect of the drugs on biodistribution and tumour localisation of monoclonal antibody 791T/36, mice with xenografts of osteosarcoma 791T were injected intraperitoneally with a mixture of 5 g of '3'I labelled 791T/36 monoclonal antibody mixed with 5 .g 1251I labelled normal
IgG2b (isolated from normal mouse serum). The preparations had been labelled to a specific activity of approximately 1 mCi mg-' by an lodogen method (Pimm et al., 1982) .
Some mice were then given 10mgkg-' of propranolol or pindolol intraperitoneally 0.5, 19, 25, 42 and 50 hours later. They were killed at 72 hours and the count rates of the two radioiodines determined on weighed samples of tissue in relation to a sample of injected material. This schedule of repeated injection of the drugs was given based on the observation of Bomber et al. (1986) that the effects of the drugs on tumour blood flow were transient, lasting no more than 30 minutes, while the localisation of antibody into tumour is a slower process, taking two to three days to achieve good discrimination between tumour and normal tissues (Pimm et al., 1982) . The '"'I labelled antibody showed localisation in tumour, in keeping with previous findings in this antibody tumour xenograft system (Pimm et al., 1982) , with a mean of 10% of the dose g-' of tumour compared with 4.6% for blood and much lower values for all normal tissues (Table II) . In propranolol treated mice there were no significant alterations in blood, tumour or other organ levels of the antibody. The same was found in pindolol treated mice, although here there was about a four fold increase in the level of radiolabel in the intestine (stomach and small and large intestine were counted together). As expected 1251 labelled control IgG2b showed no tumour localisation. Again neither propranolol nor pindolol had any significant effect on the biodistribution of the immunoglobulin, except that pindolol produced a significant increase in radiolabel levels in the intestine.
In this biodistribution experiment, the whole body retention of the two radiolabels (taken as a measure of the rates of catabolism of the immunoglobulins) were not significantly affected by propranolol treatment. Thus there was 39.1 ± 3.3% survival of '25I from control IgG2b in untreated mice and 39.3 ± 4.7% in propranolol treated. The values for "'I from the antibody were 33.2 ± 3.3% in controls and 31.8 ± 4.8% in propranol treated. However, the values in pindolol treated mice were significantly higher at 49.7 ± 3.7% for the 1251I of control IgG2b and 45.8 ± 4.1% for 3'I of the antibody (P <0.05, Student's t test for both radiolabels). This difference could be accounted for only partly by the greater retention of the radiolabels in the intestine, with an average greater level in the whole intestine of 3.9% for the '"'I labelled antibody and 4.6% for 1251I labelled IgG2b com- imaging and the systemic toxicity of immunoconjugates given for therapy.
In conclusion these studies suggest that beta blockers may not give highly effective or consistent increases in tumour blood flow and therefore may not be very effective in enhancing tumour localisation of monoclonal antibodies for tumour imaging or drug targeting. These findings do not preclude the examination of other drugs capable of altering tumour blood flow, including other vasoactive drugs (Zeissman et al., 1985; Burton & Gray, 1987; Smyth et al., 1988) . However, the present findings emphasise that if the intention is to enhance tumour localisation of monoclonal antibodies or other agents then due consideration must be given not only to tumour blood flow rates but also to the relative and absolute levels of the targeting vector in tumour and in other organs, and to whether there is any change in the overall catabolism of the vector.
